Evogene
EVGN
Evogene (EVGN) news
Recent news
EvoGene Ltd: quarterly net loss reduced to about $1.8 million
EvoGene Ltd. (NASDAQ: EVGN) reported a quarterly net loss of approximately $1.8 million for the first quarter of 2026, a reduction compared to last year net loss of $3.0 million. The company attributed this improvement to a combination of lower operating expenses and a modest increase in revenues,…
AInvest Wire · Aug 18, 2026EvoGene Ltd: expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million
AInvest Wire · Aug 18, 2026Leon Recanati reports 5.7% stake in Evogene Ltd as of August 4 - SEC filing
AInvest Wire · Aug 11, 2026L.I.A. Pure Capital Ltd says on July 26, sent email to Evogene Ltd regarding demand letter previously disclosed in the Schedule 13D - SEC filing
AInvest Wire · Jul 27, 2026EvoGene Ltd. and Eleo Inc. announce collaboration to develop next-generation oral small-molecule PCSK9 pathway inhibitors for hyperlipidemia and cardiovascular diseases
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.